- Home
- CPRI vs TARS Comparison
CPRI vs TARS Comparison
Compare CPRI & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CPRI | TARS |
|---|---|---|
| Founded | 1981 | 2016 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.8B |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CPRI | TARS |
|---|---|---|
| Price | $24.49 | $81.08 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 9 |
| Target Price | $26.55 | ★ $76.56 |
| AVG Volume (30 Days) | ★ 2.4M | 549.1K |
| Earning Date | 02-04-2026 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,369,000,000.00 | $366,100,000.00 |
| Revenue This Year | N/A | $147.24 |
| Revenue Next Year | $2.10 | $53.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 182.44 |
| 52 Week Low | $11.86 | $38.51 |
| 52 Week High | $28.27 | $85.25 |
Technical Indicators
Market Signals| Indicator | CPRI | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 45.75 | 53.02 |
| Support Level | $24.17 | $79.84 |
| Resistance Level | $25.11 | $83.94 |
| Average True Range (ATR) | 0.60 | 2.73 |
| MACD | -0.28 | -0.28 |
| Stochastic Oscillator | 9.19 | 50.25 |
Price Performance
Historical ComparisonAbout CPRI Capri Holdings Limited
Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. Capri also owns a third brand, Versace, but has agreed to sell it to Prada. John Idol has served as Capri's CEO since 2003.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.